莫桑比克南部农村地区在四次 COVID-19 之后的 SARS-CoV-2 高暴露率:基于社区的血清流行病学调查

IF 4.3 4区 医学 Q1 INFECTIOUS DISEASES Influenza and Other Respiratory Viruses Pub Date : 2024-06-05 DOI:10.1111/irv.13332
Áuria de Jesus, Rita Ernesto, Arsénia J. Massinga, Felizarda Nhacolo, Khátia Munguambe, Alcido Timana, Arsénio Nhacolo, Augusto Messa Jr., Sérgio Massora, Valdemiro Escola, Sónia Enosse, Rufino Gunjamo, Carlos Funzamo, Jason M. Mwenda, Joseph Okeibunor, Alberto Garcia-Basteiro, Caterina Guinovart, Alfredo Mayor, Inácio Mandomando
{"title":"莫桑比克南部农村地区在四次 COVID-19 之后的 SARS-CoV-2 高暴露率:基于社区的血清流行病学调查","authors":"Áuria de Jesus,&nbsp;Rita Ernesto,&nbsp;Arsénia J. Massinga,&nbsp;Felizarda Nhacolo,&nbsp;Khátia Munguambe,&nbsp;Alcido Timana,&nbsp;Arsénio Nhacolo,&nbsp;Augusto Messa Jr.,&nbsp;Sérgio Massora,&nbsp;Valdemiro Escola,&nbsp;Sónia Enosse,&nbsp;Rufino Gunjamo,&nbsp;Carlos Funzamo,&nbsp;Jason M. Mwenda,&nbsp;Joseph Okeibunor,&nbsp;Alberto Garcia-Basteiro,&nbsp;Caterina Guinovart,&nbsp;Alfredo Mayor,&nbsp;Inácio Mandomando","doi":"10.1111/irv.13332","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Mozambique was one of many African countries with limited testing capacity for SARS-CoV-2. Serosurveys, an alternative to estimate the real exposure to understand the epidemiology and transmission dynamics, have been scarce in Mozambique. Herein, we aimed to estimate the age-specific seroprevalence of SARS-CoV-2 in the general population of the Manhiça District, at four time points, for evaluating dynamics of exposure and the impact of vaccination.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We conducted four community-based seroepidemiological surveys separated by 3 months between May 2021 and June 2022 to assess the prevalence of SARS-CoV-2 antibodies. An age-stratified (0–19, 20–39, 40–59, and ≥ 60 years) sample of 4810 individuals was randomly selected from demographic surveillance database, and their blood samples were analyzed using WANTAI SARS-CoV-2 IgG + IgM ELISA. Nasopharyngeal swabs from a subsample of 2209 participants were also assessed for active infection by RT-qPCR.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>SARS-CoV-2 seroprevalence increased from 27.6% in the first survey (May 2021) to 63.6%, 91.2%, and 91.1% in the second (October 2021), third (January 2022), and fourth (May 2022) surveys, respectively. Seroprevalence in individuals &lt; 18 years, who were not eligible for vaccination, increased from 23.1% in the first survey to 87.1% in the fourth. The prevalence of active infection was below 10.1% in all surveys.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>A high seroprevalence to SARS-CoV-2 was observed in the study population, including individuals not eligible for vaccination at that time, particularly after circulation of the highly transmissible Delta variant. These data are important to inform decision making on the vaccination strategies in the context of pandemic slowdown in Mozambique.</p>\n </section>\n </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"18 6","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.13332","citationCount":"0","resultStr":"{\"title\":\"High SARS-CoV-2 Exposure in Rural Southern Mozambique After Four Waves of COVID-19: Community-Based Seroepidemiological Surveys\",\"authors\":\"Áuria de Jesus,&nbsp;Rita Ernesto,&nbsp;Arsénia J. Massinga,&nbsp;Felizarda Nhacolo,&nbsp;Khátia Munguambe,&nbsp;Alcido Timana,&nbsp;Arsénio Nhacolo,&nbsp;Augusto Messa Jr.,&nbsp;Sérgio Massora,&nbsp;Valdemiro Escola,&nbsp;Sónia Enosse,&nbsp;Rufino Gunjamo,&nbsp;Carlos Funzamo,&nbsp;Jason M. Mwenda,&nbsp;Joseph Okeibunor,&nbsp;Alberto Garcia-Basteiro,&nbsp;Caterina Guinovart,&nbsp;Alfredo Mayor,&nbsp;Inácio Mandomando\",\"doi\":\"10.1111/irv.13332\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Mozambique was one of many African countries with limited testing capacity for SARS-CoV-2. Serosurveys, an alternative to estimate the real exposure to understand the epidemiology and transmission dynamics, have been scarce in Mozambique. Herein, we aimed to estimate the age-specific seroprevalence of SARS-CoV-2 in the general population of the Manhiça District, at four time points, for evaluating dynamics of exposure and the impact of vaccination.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>We conducted four community-based seroepidemiological surveys separated by 3 months between May 2021 and June 2022 to assess the prevalence of SARS-CoV-2 antibodies. An age-stratified (0–19, 20–39, 40–59, and ≥ 60 years) sample of 4810 individuals was randomly selected from demographic surveillance database, and their blood samples were analyzed using WANTAI SARS-CoV-2 IgG + IgM ELISA. Nasopharyngeal swabs from a subsample of 2209 participants were also assessed for active infection by RT-qPCR.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>SARS-CoV-2 seroprevalence increased from 27.6% in the first survey (May 2021) to 63.6%, 91.2%, and 91.1% in the second (October 2021), third (January 2022), and fourth (May 2022) surveys, respectively. Seroprevalence in individuals &lt; 18 years, who were not eligible for vaccination, increased from 23.1% in the first survey to 87.1% in the fourth. The prevalence of active infection was below 10.1% in all surveys.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>A high seroprevalence to SARS-CoV-2 was observed in the study population, including individuals not eligible for vaccination at that time, particularly after circulation of the highly transmissible Delta variant. These data are important to inform decision making on the vaccination strategies in the context of pandemic slowdown in Mozambique.</p>\\n </section>\\n </div>\",\"PeriodicalId\":13544,\"journal\":{\"name\":\"Influenza and Other Respiratory Viruses\",\"volume\":\"18 6\",\"pages\":\"\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2024-06-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.13332\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Influenza and Other Respiratory Viruses\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/irv.13332\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Influenza and Other Respiratory Viruses","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/irv.13332","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

背景 莫桑比克是 SARS-CoV-2 检测能力有限的许多非洲国家之一。在莫桑比克,血清调查是估算真实接触率以了解流行病学和传播动态的另一种方法,但这种方法在莫桑比克很少见。在此,我们旨在估算曼希萨区普通人群在四个时间点的 SARS-CoV-2 特定年龄血清流行率,以评估暴露动态和疫苗接种的影响。 方法 我们在 2021 年 5 月至 2022 年 6 月期间进行了四次社区血清流行病学调查,每次间隔 3 个月,以评估 SARS-CoV-2 抗体的流行情况。我们从人口监测数据库中随机抽取了4810人作为年龄分层样本(0-19岁、20-39岁、40-59岁和≥60岁),并使用WANTAI SARS-CoV-2 IgG + IgM ELISA对他们的血样进行了分析。此外,还通过 RT-qPCR 对 2209 名参与者的鼻咽拭子进行了活动性感染评估。 结果 SARS-CoV-2 血清流行率从第一次调查(2021 年 5 月)的 27.6%,分别上升到第二次调查(2021 年 10 月)、第三次调查(2022 年 1 月)和第四次调查(2022 年 5 月)的 63.6%、91.2% 和 91.1%。不符合接种条件的 18 岁人群的血清流行率从第一次调查的 23.1%上升到第四次调查的 87.1%。在所有调查中,活动性感染率均低于 10.1%。 结论 在研究人群中观察到 SARS-CoV-2 的高血清流行率,包括当时不符合疫苗接种条件的人,尤其是在高传播性的 Delta 变种流行之后。这些数据对于在莫桑比克疫情减缓的背景下制定疫苗接种策略非常重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
High SARS-CoV-2 Exposure in Rural Southern Mozambique After Four Waves of COVID-19: Community-Based Seroepidemiological Surveys

Background

Mozambique was one of many African countries with limited testing capacity for SARS-CoV-2. Serosurveys, an alternative to estimate the real exposure to understand the epidemiology and transmission dynamics, have been scarce in Mozambique. Herein, we aimed to estimate the age-specific seroprevalence of SARS-CoV-2 in the general population of the Manhiça District, at four time points, for evaluating dynamics of exposure and the impact of vaccination.

Methods

We conducted four community-based seroepidemiological surveys separated by 3 months between May 2021 and June 2022 to assess the prevalence of SARS-CoV-2 antibodies. An age-stratified (0–19, 20–39, 40–59, and ≥ 60 years) sample of 4810 individuals was randomly selected from demographic surveillance database, and their blood samples were analyzed using WANTAI SARS-CoV-2 IgG + IgM ELISA. Nasopharyngeal swabs from a subsample of 2209 participants were also assessed for active infection by RT-qPCR.

Results

SARS-CoV-2 seroprevalence increased from 27.6% in the first survey (May 2021) to 63.6%, 91.2%, and 91.1% in the second (October 2021), third (January 2022), and fourth (May 2022) surveys, respectively. Seroprevalence in individuals < 18 years, who were not eligible for vaccination, increased from 23.1% in the first survey to 87.1% in the fourth. The prevalence of active infection was below 10.1% in all surveys.

Conclusions

A high seroprevalence to SARS-CoV-2 was observed in the study population, including individuals not eligible for vaccination at that time, particularly after circulation of the highly transmissible Delta variant. These data are important to inform decision making on the vaccination strategies in the context of pandemic slowdown in Mozambique.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
7.20
自引率
4.50%
发文量
120
审稿时长
6-12 weeks
期刊介绍: Influenza and Other Respiratory Viruses is the official journal of the International Society of Influenza and Other Respiratory Virus Diseases - an independent scientific professional society - dedicated to promoting the prevention, detection, treatment, and control of influenza and other respiratory virus diseases. Influenza and Other Respiratory Viruses is an Open Access journal. Copyright on any research article published by Influenza and Other Respiratory Viruses is retained by the author(s). Authors grant Wiley a license to publish the article and identify itself as the original publisher. Authors also grant any third party the right to use the article freely as long as its integrity is maintained and its original authors, citation details and publisher are identified.
期刊最新文献
Inpatient Burden of Respiratory Syncytial Virus Infection and Influenza in Children Younger Than 5 Years in Japan, 2011–2022: A Database Study Influenza in Adults Seeking Care at Seven European Emergency Departments: A Prospective Active Surveillance During the 2019–2020 Influenza Season Technological Barriers to Routine Genomic Surveillance for Vaccine Development Against SARS-CoV-2 in Africa: A Systematic Review Virological and Clinical Outcomes of Influenza Outpatients Treated With Baloxavir, Oseltamivir, or Laninamivir in the 2023–2024 Season Impact of Age and Comorbid Conditions on Incidence Rates of COVID-19-Associated Hospitalizations, 2020–2021
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1